Pemetrexed disodium (Alimta)

Key facts

Invented name
Alimta
Active substance
pemetrexed disodium
Therapeutic area
Oncology
Decision number
P/34/2009
PIP number
Pemetrexed disodium (Alimta)
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
  • Carcinoma of the head and neck (Covered by class waiver: oropharyngeal epithelial carcinoma, excluding nasopharyngeal carcinoma)
  • Malignant pleural mesothelioma
Route(s) of administration
Intravenous use
Contact for public enquiries
Eli Lilly and Company Limited (US)

Tel.: +1 31 75448941
E-mail: wagle_asvari@lilly.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating